ストックスクリーナーアプリを入手
5.81
4.75%
-0.29
Eyepoint Pharmaceuticals Inc (EYPT) 最新ニュース
Eyepoint projects DURAVYU Phase 3 enrollment completion by H2 2025 amid strong clinical trial momentum - MSN
EyePoint Pharmaceuticals (EYPT): Analyst Maintains Buy Rating, Lowers Price Target | EYPT Stock News - GuruFocus
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q1 2025 Earnings Call Transcript - Insider Monkey
EyePoint Pharma’s Promising Q1 2025 Financial Results - TipRanks
EyePoint Pharmaceuticals: Q1 Earnings Snapshot - Midland Daily News
EyePoint Pharmaceuticals (EYPT) Reports Growth Amidst Trial Developments - GuruFocus
Transcript : EyePoint Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 07, 2025 - marketscreener.com
Earnings call transcript: EyePoint Pharmaceuticals Q1 2025: Revenue Surges - Investing.com
EyePoint Pharmaceuticals (EYPT) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
EyePoint (EYPT) Sees Strong Q1 Revenue Growth and Advances in DURAVYU Trials | EYPT Stock News - GuruFocus
EyePoint Pharmaceuticals Inc Surpasses Revenue Estimates with $24.5 Million in Q1 2025, EPS of ($0.65) Slightly Beats Expectations - GuruFocus
EyePoint Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments - EyePoint Pharmaceuticals
EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025 - EyePoint Pharmaceuticals
A Peek at EyePoint Pharmaceuticals's Future Earnings - Nasdaq
EyePoint Pharmaceuticals to Host Conference Call for Q1 2025 Financial Results on May 7 - Nasdaq
EyePoint Pharmaceuticals Q1 2025 Earnings and Corporate Updates: Join Live Call May 7 - Stock Titan
Pars Planitis Market Set to Grow Substantially Through 2032, - openPR.com
EyePoint (EYPT) Offers Stock Options as Inducement for New Hires | EYPT Stock News - GuruFocus
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | EYPT Stock News - GuruFocus
Eyepoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
EyePoint Expands Team with Strategic Stock Options Package Worth $370K - Stock Titan
How the (EYPT) price action is used to our Advantage - news.stocktradersdaily.com
Nano Silicon Drug Delivery Platform Market to Witness Massive - openPR.com
Ex-Dividend Date Nearing for These 10 Stocks – Week of April 7, 2025 - The Globe and Mail
EyePoint Pharmaceuticals' US$84m Market Cap Fall Books Insider Losses - simplywall.st
EyePoint Pharmaceuticals at RBC Conference: Insights on Duravu’s Promise By Investing.com - Investing.com Canada
Compliance - EyePoint Pharmaceuticals
Working At Eyepoint - EyePoint Pharmaceuticals
Here's Why We're Watching EyePoint Pharmaceuticals' (NASDAQ:EYPT) Cash Burn Situation - Yahoo Finance
Long Term Trading Analysis for (EYPT) - news.stocktradersdaily.com
pSivida Corp Announces Transformative Acquisition Of Icon Bioscience - Reuters
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Recommendation of “Buy” from Analysts - Defense World
EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference - The Manila Times
EyePoint's CEO Takes Center Stage: Key Updates Coming at RBC Ophthalmology Conference - Stock Titan
What is Chardan Capital’s Estimate for EYPT FY2026 Earnings? - Defense World
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Bought by Bank of New York Mellon Corp - Defense World
3 US Healthcare Stocks That Might Be Undervalued 2025 - Value The Markets
(EYPT) Investment Report - news.stocktradersdaily.com
Mizuho maintains EyePoint stock Outperform with $30 target By Investing.com - Investing.com Australia
Mizuho maintains EyePoint stock Outperform with $30 target - Investing.com India
EyePoint Expands Team with New Hires, Awards $6.52 Stock Options - Stock Titan
Li Auto, Xponential Fitness And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga India
StockNews.com Upgrades EyePoint Pharmaceuticals (NASDAQ:EYPT) to “Sell” - Defense World
EyePoint Pharmaceuticals at Leerink’s Conference: DuraView’s Promising Potential By Investing.com - Investing.com Canada
Q1 EPS Estimate for EyePoint Pharmaceuticals Cut by Analyst - Defense World
Research Analysts Set Expectations for EYPT FY2025 Earnings - Defense World
EyePoint Pharmaceuticals Inc (EYPT) Reports Q3 2023 Financial Re - GuruFocus.com
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Full-Year Results: Here's What Analysts Are Forecasting For This Year - simplywall.st
Rhumbline Advisers Purchases 12,443 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
Chardan Capital Reiterates “Buy” Rating for EyePoint Pharmaceuticals (NASDAQ:EYPT) - Defense World
HC Wainwright Reaffirms Buy Rating for EyePoint Pharmaceuticals (NASDAQ:EYPT) - Defense World
Demystifying EyePoint Pharmaceuticals: Insights From 4 Analyst Reviews - Benzinga
0.84%
0.15%
大文字化:
|
ボリューム (24 時間):